Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

22.81
-0.2900-1.26%
Post-market: 22.810.00000.00%19:30 EDT
Volume:471.46K
Turnover:10.76M
Market Cap:1.51B
PE:-7.34
High:24.23
Open:23.29
Low:22.40
Close:23.10
52wk High:30.99
52wk Low:10.30
Shares:66.17M
Float Shares:36.76M
Volume Ratio:0.96
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1097
EPS(LYR):-2.5230
ROE:-41.01%
ROA:-26.14%
PB:3.22
PE(LYR):-9.04

Loading ...

Bicara Therapeutics Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $42

THOMSON REUTERS
·
May 11

Bicara Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
May 11

Bicara Therapeutics Inc expected to post a loss of 65 cents a share - Earnings Preview

Reuters
·
May 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 08

Biocon chair Kiran Mazumdar-Shaw identifies successor as Indian pharma firm plans transition

Reuters
·
May 05

Bicara Therapeutics to report first-quarter 2026 results, host conference call

Reuters
·
May 04

Bicara CMO David Raben disposes 5,500 shares worth $125,830

Reuters
·
Apr 29

Bicara Therapeutics announces annual shareholder meeting online

Reuters
·
Apr 27

Bicara CFO Ivan Hyep disposes 9,200 shares for $211,614

Reuters
·
Apr 23

Bicara Therapeutics CEO Claire Mazumdar disposes of common shares worth $354,145.5

Reuters
·
Apr 21

Bicara President, COO Ryan Cohlhepp disposes 12,500 shares for $287,591.25

Reuters
·
Apr 18

Bicara Therapeutics’ Earnings Call Highlights Pivotal Pivot

TIPRANKS
·
Apr 07

JonesTrading Sticks to Its Buy Rating for Bicara Therapeutics Inc. (BCAX)

TIPRANKS
·
Apr 07

Bicara Therapeutics grants new employee stock option for 44,175 shares under inducement plan

Reuters
·
Apr 03

Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 03

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Apr 03

Bicara Therapeutics management to meet with Citizens

TIPRANKS
·
Apr 02

Stock Track | Bicara Therapeutics Soars 5.20% Intraday on Analyst Price Target Increases and Positive Forecasts

Stock Track
·
Apr 01

Wedbush Sticks to Its Buy Rating for Bicara Therapeutics Inc. (BCAX)

TIPRANKS
·
Mar 31

Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday

Benzinga_recent_news
·
Mar 31